Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/23649537/ below:

PSA screening and deaths from prostate cancer after diagnosis--a population based analysis

• PMID: 23649537
• DOI: 10.1002/pros.22680

Item in Clipboard

Mitchell S Wachtel et al. Prostate. 2013 Sep.

• PMID: 23649537
• DOI: 10.1002/pros.22680

Item in Clipboard

Background: The United States Preventative Health Task Force recently recommended prostate specific antigen (PSA) screening be abandoned, believing the results of prior studies failed to show benefits that outweighed risks. Prior analyses did not include a complete 10 year follow-up in their analyses.

Methods: SEER rate sessions were used to obtain for U.S. White and Black men age-adjusted incidence rates for prostate cancer, in total and by loco-regional and distant (D2) spread for 1983-2009, as well as for prostate cancer diagnoses with associated prostate cancer deaths within 10 years of diagnosis (incidence based mortality rates) for 1983-1999. The SEER-Stat Program was used to tabulate rate estimates and calculate standard errors. The Joinpoint Regression Program was used to provide estimates and 95% confidence intervals (CI) of annual percent changes (APC) and times at which APC changed (joinpoints), as well as to test for parallelism to see if APC's differed between groups of rates.

Results: All analyses showed a 1991-1993 joinpoint, consistent with an impact of PSA screening. Between 1991 and 1999, incidence based mortality rates showed a decline for Whites of 10.9% (CI 9.2%-12.7%) and for Blacks of 11.6% (CI 9.7%-13.4%); incidence based mortality and D2 spread rate curves were similar (P > 0.05, test for parallelism).

Conclusion: Incidence based mortality declined by about 10% per year between 1991 and 1999 in a fashion similar to that of D2 spread, but not loco-regional spread or overall, incidence.

Keywords: PSA; mortality; prostate cancer; screening.

Copyright © 2013 Wiley Periodicals, Inc.

PubMed Disclaimer

• Prostate cancer and prostate-specific antigen (PSA) screening in Austria.

  Vutuc C, Schernhammer ES, Haidinger G, Waldhör T. Vutuc C, et al. Wien Klin Wochenschr. 2005 Jul;117(13-14):457-61. doi: 10.1007/s00508-005-0395-y. Wien Klin Wochenschr. 2005. PMID: 16091872

• Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach.

  Etzioni R, Gulati R, Falcon S, Penson DF. Etzioni R, et al. Med Decis Making. 2008 May-Jun;28(3):323-31. doi: 10.1177/0272989X07312719. Epub 2008 Mar 4. Med Decis Making. 2008. PMID: 18319508

• Prostate cancer mortality in the Finnish randomized screening trial.

  Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L, Stenman UH, Kujala P, Auvinen A. Kilpeläinen TP, et al. J Natl Cancer Inst. 2013 May 15;105(10):719-25. doi: 10.1093/jnci/djt038. Epub 2013 Mar 11. J Natl Cancer Inst. 2013. PMID: 23479454 Clinical Trial.

• Landmarks in prostate cancer screening.

  Schröder FH. Schröder FH. BJU Int. 2012 Oct;110 Suppl 1:3-7. doi: 10.1111/j.1464-410X.2012.011428.x. BJU Int. 2012. PMID: 23046034 Review.

• Screening for prostate cancer: the current evidence and guidelines controversy.

  Gomella LG, Liu XS, Trabulsi EJ, Kelly WK, Myers R, Showalter T, Dicker A, Wender R. Gomella LG, et al. Can J Urol. 2011 Oct;18(5):5875-83. Can J Urol. 2011. PMID: 22018148 Review.

• Clinical proteomics for prostate cancer: understanding prostate cancer pathology and protein biomarkers for improved disease management.

  Tonry C, Finn S, Armstrong J, Pennington SR. Tonry C, et al. Clin Proteomics. 2020 Nov 20;17(1):41. doi: 10.1186/s12014-020-09305-7. Clin Proteomics. 2020. PMID: 33292167 Free PMC article. Review.

• Impact of Age, Race and Socio-economic Status on Temporal Trends in Late-Stage Prostate Cancer Diagnosis in Florida.

  Goovaerts P, Xiao H, Gwede CK, Tan F, Huang Y, Adunlin G, Ali A. Goovaerts P, et al. Spat Stat. 2015 Nov 1;14(Pt 100):321-337. doi: 10.1016/j.spasta.2015.07.002. Spat Stat. 2015. PMID: 26644992 Free PMC article.

• The Effect of Advances in Lung-Cancer Treatment on Population Mortality.

  Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, Mariotto AB, Lowy DR, Feuer EJ. Howlader N, et al. N Engl J Med. 2020 Aug 13;383(7):640-649. doi: 10.1056/NEJMoa1916623. N Engl J Med. 2020. PMID: 32786189 Free PMC article.

• Countries with high circumcision prevalence have lower prostate cancer mortality.

  Wachtel MS, Yang S, Morris BJ. Wachtel MS, et al. Asian J Androl. 2016 Jan-Feb;18(1):39-42. doi: 10.4103/1008-682X.159713. Asian J Androl. 2016. PMID: 26323559 Free PMC article.

• Trends in Lung and Bronchus, Prostate, Female Breast, and Colon and Rectum Cancers Incidence and Mortality in Oklahoma and the United States from 1999 to 2012.

  Duong Q, Hill CL Jr, Janitz AE, Campbell JE. Duong Q, et al. J Okla State Med Assoc. 2016 Jul-Aug;109(7-8):347-353. J Okla State Med Assoc. 2016. PMID: 27885304 Free PMC article.

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3